Acasti Pharma Past Earnings Performance
Past criteria checks 0/6
Acasti Pharma has been growing earnings at an average annual rate of 6.3%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 9.9% per year.
Key information
6.3%
Earnings growth rate
55.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -9.9% |
| Return on equity | -20.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Acasti Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -13 | 7 | 5 |
| 31 Dec 23 | 0 | -39 | 8 | 5 |
| 30 Sep 23 | 0 | -40 | 8 | 6 |
| 30 Jun 23 | 0 | -42 | 8 | 8 |
| 31 Mar 23 | 0 | -42 | 8 | 10 |
| 31 Dec 22 | 0 | -17 | 5 | 11 |
| 30 Sep 22 | 0 | -17 | 5 | 10 |
| 30 Jun 22 | 0 | -11 | 6 | 8 |
| 31 Mar 22 | 0 | -10 | 7 | 6 |
| 31 Dec 21 | 0 | -12 | 9 | 4 |
| 30 Sep 21 | 0 | -11 | 8 | 2 |
| 30 Jun 21 | 0 | -18 | 7 | 3 |
| 31 Mar 21 | 0 | -20 | 7 | 4 |
| 31 Dec 20 | 0 | 3 | 8 | 6 |
| 30 Sep 20 | 0 | -6 | 9 | 9 |
| 30 Jun 20 | 0 | -21 | 10 | 12 |
| 31 Mar 20 | 0 | -26 | 8 | 16 |
| 31 Dec 19 | 0 | -56 | 7 | 23 |
| 30 Sep 19 | 0 | -46 | 6 | 26 |
| 30 Jun 19 | 0 | -42 | 5 | 29 |
| 31 Mar 19 | 0 | -39 | 4 | 29 |
| 31 Dec 18 | 0 | -31 | 4 | 25 |
| 30 Sep 18 | 0 | -34 | 3 | 22 |
| 30 Jun 18 | 0 | -20 | 3 | 17 |
| 31 Mar 18 | 0 | -17 | 3 | 12 |
| 31 Mar 17 | 0 | -8 | 2 | 5 |
| 30 Nov 16 | 0 | -7 | 2 | 5 |
| 31 Aug 16 | 0 | -7 | 2 | 6 |
| 31 May 16 | 0 | -6 | 2 | 6 |
| 29 Feb 16 | 0 | -5 | 2 | 5 |
| 30 Nov 15 | 0 | -5 | 0 | 7 |
| 31 Aug 15 | 0 | -1 | 1 | 7 |
| 31 May 15 | 0 | -3 | 2 | 8 |
| 28 Feb 15 | 0 | -1 | 3 | 7 |
| 30 Nov 14 | 0 | -2 | 5 | 5 |
| 31 Aug 14 | 0 | -8 | 7 | 5 |
| 31 May 14 | 1 | -8 | 7 | 4 |
| 28 Feb 14 | 0 | -10 | 4 | 5 |
| 30 Nov 13 | 0 | -10 | 6 | 4 |
| 31 Aug 13 | 1 | -8 | 5 | 4 |
Quality Earnings: A1P0 is currently unprofitable.
Growing Profit Margin: A1P0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A1P0 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare A1P0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A1P0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: A1P0 has a negative Return on Equity (-20.82%), as it is currently unprofitable.